Immunome (IMNM) Earnings Date & Reports

Key Takeaways

• Immunome, Inc. (IMNM) is expected to report its third-quarter 2026 results in early-to-mid November, with consensus estimates pointing to a net loss of roughly $0.61 to $0.64 per share.
• As a clinical-stage oncology company, Immunome generates minimal revenue, so investors will focus on research and development spending, cash runway, and pipeline progress rather than top-line sales.
• In its most recent quarter (Q2 2026), Immunome posted a loss of $0.65 per share, missing the consensus estimate of $0.51 per share by $0.14.
• Key clinical catalysts under watch include the Phase 3 varegacestat program for desmoid tumors and early-stage assets IM-1021 and IM-3050.
• Operating expense trends and the company's cash position will be central themes as management updates its development timeline.
• For more on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages available for deeper insights.
• You can also explore Trending AI Robots to discover AI-driven trading strategies and tools.

Earnings Context and Why It Matters

Immunome is a clinical-stage biotech focused on first-in-class and best-in-class oncology therapies, including antibody-drug conjugates (ADCs) and radioligand therapies. Because the company has no approved products, its quarterly earnings are less about revenue and more about capital efficiency, clinical execution, and pipeline momentum. Investors will be watching whether rising research and development costs are translating into meaningful clinical progress, especially as the lead candidate, varegacestat, advances through a registrational Phase 3 trial. With collaboration revenue from a prior AbbVie agreement having wound down, the update will also clarify how Immunome plans to fund continued development while preserving shareholder value.

Earnings Expectations

Analysts expect Immunome to report a net loss of approximately $0.61 to $0.64 per share for the third quarter of 2026, with consensus revenue estimates in the low hundreds of thousands of dollars, reflecting the company's pre-commercial stage. For context, Immunome reported a loss of $0.65 per share in Q2 2026, missing the consensus estimate of $0.51 per share. Historically, the company has beaten consensus EPS in only three of its last eight quarters, underscoring the difficulty of forecasting expenses for a development-stage biotech. Rather than earnings per share, investors are likely to focus on cash burn, the pace of trial enrollment, and any commentary on upcoming data readouts.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a useful companion for earnings-focused research and broader portfolio monitoring.

Market Reaction and Investor Sentiment

Sentiment heading into Immunome's third-quarter report is likely to hinge on clinical news flow rather than the financial headline numbers. Development-stage biotech stocks frequently react to pipeline milestones and cash-position updates more than to quarterly losses, and Immunome is no exception. Key risk factors include the potential for disappointing trial data, higher-than-expected research and development spending, and the possibility of future dilutive capital raises. With the company expecting to continue incurring losses for the foreseeable future, investors may remain sensitive to any signals about when additional financing could be needed.

Forward Outlook and Key Factors to Monitor

Following this earnings event, investors should watch the trajectory of the Phase 3 varegacestat program for desmoid tumors, where topline data timing and enrollment progress will be the dominant drivers of sentiment. Any updated guidance on data readouts could meaningfully influence the stock's direction.

Beyond varegacestat, early-stage assets IM-1021 (a ROR1 ADC) and IM-3050 represent additional catalysts. Initial data from IM-1021 and the planned Phase 1 initiation for IM-3050 will help investors gauge the breadth and depth of Immunome's pipeline.

Cost discipline and cash runway also warrant close attention. As clinical activity intensifies, research and development expenses are expected to rise, making the company's liquidity position and any future financing plans an important area of focus. Investors will want to understand how long current cash is sufficient to fund operations and whether future capital raises could dilute existing shareholders.

Finally, industry dynamics in targeted oncology, including competitive developments in ADC and radioligand therapies, may shape how the market interprets Immunome's progress in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations